Stockreport

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis 96% of participants receivin [Read more]